These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 20142019)

  • 21. Multiparametric risk stratification in patients with mild to moderate chronic heart failure.
    Scardovi AB; De Maria R; Coletta C; Aspromonte N; Perna S; Cacciatore G; Parolini M; Ricci R; Ceci V
    J Card Fail; 2007 Aug; 13(6):445-51. PubMed ID: 17675058
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hepatocyte growth factor is a strong predictor of mortality in patients with advanced heart failure.
    Rychli K; Richter B; Hohensinner PJ; Kariem Mahdy A; Neuhold S; Zorn G; Berger R; Mörtl D; Huber K; Pacher R; Wojta J; Niessner A; Hülsmann M
    Heart; 2011 Jul; 97(14):1158-63. PubMed ID: 21572126
    [TBL] [Abstract][Full Text] [Related]  

  • 23. N-terminal pro-atrial natriuretic peptide (N-ANP) and N-terminal pro-B-type natriuretic peptide (N-BNP) in the prediction of death and heart failure in unselected patients following acute myocardial infarction.
    Squire IB; O'Brien RJ; Demme B; Davies JE; Ng LL
    Clin Sci (Lond); 2004 Sep; 107(3):309-16. PubMed ID: 15182235
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of B-type natriuretic peptide levels in patients with heart failure with versus without mitral regurgitation.
    Mayer SA; De Lemos JA; Murphy SA; Brooks S; Roberts BJ; Grayburn PA
    Am J Cardiol; 2004 Apr; 93(8):1002-6. PubMed ID: 15081443
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of usefulness of each of five predictors of mortality and urgent transplantation in patients with advanced heart failure.
    Sachdeva A; Horwich TB; Fonarow GC
    Am J Cardiol; 2010 Sep; 106(6):830-5. PubMed ID: 20816124
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure.
    Fonarow GC; Peacock WF; Phillips CO; Givertz MM; Lopatin M;
    J Am Coll Cardiol; 2007 May; 49(19):1943-50. PubMed ID: 17498579
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Does clinician's knowledge of B-type natriuretic peptide levels translate to improvement of quality of life and less hospitalization days in patients with heart failure?
    Ancheta IB; Evans M; Miller AB; Chiong JR; Battie C
    Prog Cardiovasc Nurs; 2009 Mar; 24(1):12-8. PubMed ID: 19261138
    [TBL] [Abstract][Full Text] [Related]  

  • 28. How often we need to measure brain natriuretic peptide (BNP) blood levels in patients admitted to the hospital for acute severe heart failure? Role of serial measurements to improve short-term prognostic stratification.
    Faggiano P; Valle R; Aspromonte N; D'Aloia A; Di Tano G; Barro S; Giovinazzo P; Milani L; Lorusso R; Dei Cas L
    Int J Cardiol; 2010 Apr; 140(1):88-94. PubMed ID: 19321212
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combining natriuretic peptides and necrosis markers in determining prognosis in heart failure.
    Fonarow GC; Horwich TB
    Rev Cardiovasc Med; 2003; 4 Suppl 4():S20-8. PubMed ID: 14564225
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of prognostic significance of amino-terminal pro-brain natriuretic Peptide versus blood urea nitrogen for predicting events in patients hospitalized for heart failure.
    Shenkman HJ; Zareba W; Bisognano JD
    Am J Cardiol; 2007 Apr; 99(8):1143-5. PubMed ID: 17437744
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination of B-type natriuretic peptide and peak oxygen consumption improves risk stratification in outpatients with chronic heart failure.
    Isnard R; Pousset F; Chafirovskaïa O; Carayon A; Hulot JS; Thomas D; Komajda M
    Am Heart J; 2003 Oct; 146(4):729-35. PubMed ID: 14564330
    [TBL] [Abstract][Full Text] [Related]  

  • 32. How obesity affects the cut-points for B-type natriuretic peptide in the diagnosis of acute heart failure. Results from the Breathing Not Properly Multinational Study.
    Daniels LB; Clopton P; Bhalla V; Krishnaswamy P; Nowak RM; McCord J; Hollander JE; Duc P; Omland T; Storrow AB; Abraham WT; Wu AH; Steg PG; Westheim A; Knudsen CW; Perez A; Kazanegra R; Herrmann HC; McCullough PA; Maisel AS
    Am Heart J; 2006 May; 151(5):999-1005. PubMed ID: 16644321
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serial biomarker measurements in ambulatory patients with chronic heart failure: the importance of change over time.
    Miller WL; Hartman KA; Burritt MF; Grill DE; Rodeheffer RJ; Burnett JC; Jaffe AS
    Circulation; 2007 Jul; 116(3):249-57. PubMed ID: 17592074
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Baseline and 6-month B-type natriuretic peptide changes are independent predictors of events in patients with advanced heart failure awaiting cardiac transplantation.
    Campana C; Pasotti M; Klersy C; Alessandrino G; Albertini R; Magrini G; Ghio S; Tavazzi L
    J Cardiovasc Med (Hagerstown); 2009 Sep; 10(9):671-6. PubMed ID: 19444135
    [TBL] [Abstract][Full Text] [Related]  

  • 35. B-type natriuretic peptide-guided heart failure therapy: A meta-analysis.
    Porapakkham P; Porapakkham P; Zimmet H; Billah B; Krum H
    Arch Intern Med; 2010 Mar; 170(6):507-14. PubMed ID: 20308637
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Usefulness of N-terminal pro-brain natriuretic Peptide and brain natriuretic peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction.
    Grewal J; McKelvie RS; Persson H; Tait P; Carlsson J; Swedberg K; Ostergren J; Lonn E
    Am J Cardiol; 2008 Sep; 102(6):733-7. PubMed ID: 18773998
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optimization of the use of B-type natriuretic peptide levels for risk stratification at discharge in elderly patients with decompensated heart failure.
    Cournot M; Mourre F; Castel F; Ferrières J; Destrac S
    Am Heart J; 2008 Jun; 155(6):986-91. PubMed ID: 18513508
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Use of brain natriuretic peptide (BNP) in the diagnosis and treatment of heart failure].
    Martin-Du Pan RC; Ricou F
    Rev Med Suisse Romande; 2003 Feb; 123(2):125-8. PubMed ID: 15095695
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of growth hormone treatment on B-type natriuretic peptide as a marker of heart failure in adults with growth hormone deficiency.
    Wallaschofski H; Saller B; Spilcke-Liss E; Lerch MM; Lohmann T; Eigenthaler M
    Horm Metab Res; 2006 Oct; 38(10):656-61. PubMed ID: 17075774
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of the prognostic usefulness of N-terminal pro-brain natriuretic Peptide in patients with heart failure with versus without chronic kidney disease.
    Bruch C; Fischer C; Sindermann J; Stypmann J; Breithardt G; Gradaus R
    Am J Cardiol; 2008 Aug; 102(4):469-74. PubMed ID: 18678308
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.